Multiplexing for Efficient Product Development
By: S. Jones
IBC BioProcess International West; 2016 Mar 15-17; Oakland, CA.
In today’s competitive market, companies do not have time to develop new biopharmaceuticals in a linear path. Overlapping late stage discovery activities and early stage development is an emerging strategy that provides risk reduction while accelerating timelines. Case studies implementing this risk-reduction strategy illustrate the benefits to companies, investors, and patients, including superior biopharmaceutical candidates, easier manufacturing strategies, and shorter timelines to first-in-human studies.